Cargando…

Vismodegib in Locally Advanced Basal Cell Carcinoma in Slovenia

BACKGROUND: Vismodegib is a first-in-class inhibitor of the hedgehog pathway for treatment of locally advanced basal cell carcinoma (laBCC) and metastatic BCC. OBJECTIVES: The purpose of this study is to report outcomes of patients with laBCC, with basal cell carcinoma nevus syndrome (Gorlin Goltz s...

Descripción completa

Detalles Bibliográficos
Autores principales:	Mesti, Tanja, Sever, Maša, Ocvirk, Janja
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	S. Karger AG 2022
Materias:	Skin Cancer − Research Article
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9808722/ https://www.ncbi.nlm.nih.gov/pubmed/35896082 http://dx.doi.org/10.1159/000525612

Ejemplares similares

The cost of systemic therapy for metastatic colorectal carcinoma in Slovenia: discrepancy analysis between cost and reimbursement
por: Mesti, Tanja, et al.
Publicado: (2015)

The Five-year KRAS, NRAS and BRAF Analysis Results and Treatment Patterns in Daily Clinical Practice in Slovenia in 1(st) Line Treatment of Metastatic Colorectal (mCRC) Patients with RAS Wild-type Tumour (wtRAS) – A Real- Life Data Report 2013–2018
por: Mesti, Tanja, et al.
Publicado: (2023)

Swiss Recommendations for Cutaneous Basal Cell Carcinoma
por: Ramelyte, Egle, et al.
Publicado: (2022)

Frequency and Genomic Aspects of Intrinsic Resistance to Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Yurchenko, Andrey A., et al.
Publicado: (2022)

Treatment of Locally Advanced Basal Cell Carcinomas with Vismodegib
por: Mastronardi, Luis, et al.
Publicado: (2021)

Congenital ichthyosis patient with squamous cell carcinoma of the skin who received concurrent chemoradiation: A case report
por: Cerra-Franco, Alberto, et al.
Publicado: (2017)

18-FDG PET/CT assessment of basal cell carcinoma with vismodegib
por: Thacker, Curtis A, et al.
Publicado: (2012)

Vismodegib and orbital excision for treating locally advanced basal cell carcinoma
por: Hogarty, Daniel T, et al.
Publicado: (2018)

Malignant gliomas: old and new systemic treatment approaches
por: Mesti, Tanja, et al.
Publicado: (2016)

Benefit–risk assessment of sonidegib and vismodegib in the treatment of locally advanced basal cell carcinoma
por: García Ruiz, Antonio J, et al.
Publicado: (2022)

Vismodegib in neoadjuvant treatment of locally advanced basal cell carcinoma: First results of a multicenter, open-label, phase 2 trial (VISMONEO study): Neoadjuvant Vismodegib in Locally Advanced Basal Cell Carcinoma
por: Bertrand, Nicolas, et al.
Publicado: (2021)

Targeted Therapy for Advanced Basal-Cell Carcinoma: Vismodegib and Beyond
por: Cowey, C. Lance
Publicado: (2013)

Non-surgical Management of Locally Advanced Basal Cell Carcinoma of the Upper Extremity With Vismodegib
por: Swisher, Austin R, et al.
Publicado: (2022)

Biomarkers for Outcome in Metastatic Melanoma in First Line Treatment with Immune Checkpoint Inhibitors
por: Mesti, Tanja, et al.
Publicado: (2023)

Molecular Biomarkers and Histological Parameters Impact on Survival and Response to First- Line Systemic Therapy of Metastatic Colorectal Cancer Patients
por: Rebersek, Martina, et al.
Publicado: (2019)

Vismodegib: First-in-Class Hedgehog Pathway Inhibitor for Metastatic or Locally Advanced Basal Cell Carcinoma
por: Nix, Nancy M., et al.
Publicado: (2014)

Vismodegib: the Proof of Concept in Basal Cell Carcinoma
por: Berrada, Narjiss, et al.
Publicado: (2014)

Long-Term Efficacy of Photodynamic Therapy with Fractionated 5-Aminolevulinic Acid 20% versus Conventional Two-Stage Topical Methyl Aminolevulinate for Superficial Basal-Cell Carcinoma
por: van Delft, Lieke C.J., et al.
Publicado: (2022)

Vismodegib for giant, locally advanced, basal cell carcinoma and its complex position in clinical practice
por: Koekelkoren, Fabiënne H.J., et al.
Publicado: (2019)

Profile of vismodegib and its potential in the treatment of advanced basal cell carcinoma
por: Macha, Muzafar A, et al.
Publicado: (2013)

Vismodegib: A smoothened inhibitor for the treatment of advanced basal cell carcinoma
por: Aditya, Suruchi, et al.
Publicado: (2013)

Rapid response to vismodegib in a patient with advanced basal cell carcinoma
por: Vornicova, Olga, et al.
Publicado: (2015)

Vismodegib treatment in advanced basal cell carcinomas: Real‐life experience
por: Villani, Alessia, et al.
Publicado: (2021)

Vismodegib for Locally Advanced Periocular and Orbital Basal Cell Carcinoma: A Review of 15 Consecutive Cases
por: Wong, Kai Yuen, et al.
Publicado: (2017)

Treatment of periocular basal cell carcinoma with neoadjuvant vismodegib
por: Su, Maxwell G., et al.
Publicado: (2020)

Adverse Events During Immunotherapy in Slovenian Patients with Metastatic Melanoma Reveal a Positive Correlation with Better Treatment Outcomes
por: Mesti, Tanja, et al.
Publicado: (2021)

A Matching-Adjusted Indirect Comparison of Sonidegib and Vismodegib in Advanced Basal Cell Carcinoma
por: Odom, Dawn, et al.
Publicado: (2017)

Safety and efficacy of vismodegib in patients aged ≥65 years with advanced basal cell carcinoma
por: Chang, Anne Lynn S., et al.
Publicado: (2016)

Neoadjuvant Therapy for Non-melanoma Skin Cancer: Updated Therapeutic Approaches for Basal, Squamous, and Merkel Cell Carcinoma
por: Zelin, Enrico, et al.
Publicado: (2021)

Bevacizumab and irinotecan in recurrent malignant glioma, a single institution experience
por: Mesti, Tanja, et al.
Publicado: (2015)

Basal cell carcinoma: multimodal treatment and the role of neoadjuvant vismodegib
por: Martins, Pedro Carvalho, et al.
Publicado: (2019)

Investigational agents in metastatic basal cell carcinoma: focus on vismodegib
por: Batty, Nicolas, et al.
Publicado: (2012)

Complete pathologic clearance with vismodegib in advanced basal cell carcinoma of the scalp with cranial invasion
por: Dodson, Joseph, et al.
Publicado: (2022)

Tailored Toxicity-Driven Administration of Vismodegib in Patients With Multiple or Locally Advanced Basal Cell Carcinoma: A Pilot Analysis
por: Tronconi, Maria Chiara, et al.
Publicado: (2020)

Intracranial regression of an advanced basal cell carcinoma using sonidegib and itraconazole after failure with vismodegib
por: Yoon, Jaeyoung, et al.
Publicado: (2017)

Granulation tissue masquerading as basal cell carcinoma after treatment with vismodegib
por: Miedema, Jayson, et al.
Publicado: (2017)

Gene-Related Response of Basal Cell Carcinoma to Biologic Treatment with Vismodegib
por: Sternfeld, Amir, et al.
Publicado: (2020)

Vismodegib dose reduction effective when combined with itraconazole for the treatment of advanced basal cell carcinoma
por: Yoon, Jaeyoung
Publicado: (2020)

Vismodegib for Preservation of Visual Function in Patients with Advanced Periocular Basal Cell Carcinoma: The VISORB Trial
por: Kahana, Alon, et al.
Publicado: (2021)

Combination Trimodality Therapy Using Vismodegib for Basal Cell Carcinoma of the Face
por: Block, Alec M., et al.
Publicado: (2015)

Cannot write session to /tmp/vufind_sessions/sess_41eac255hqbba0bqejrk96h251